GtoPdb is requesting financial support from commercial users. Please see our sustainability page for more information.

obinutuzumab   Click here for help

GtoPdb Ligand ID: 6941

Synonyms: GA-101 | GA101 | Gazyva®
Approved drug Immunopharmacology Ligand
obinutuzumab is an approved drug (FDA (2013), EMA (2014))
Compound class: Antibody
Comment: Obinutuzumab is a third-generation, humanized and glyco-engineered anti-CD20 IgG1 mAb. Prior to 2009 obinutuzumab was known as afutuzumab.
Annotated peptide sequences for this antibody are available from its IMGT/mAb-DB record.
IUPHAR Pharmacology Education Project (PEP) logo

View more information in the IUPHAR Pharmacology Education Project: obinutuzumab

Immunopharmacology Disease
Disease X-Refs Comment References
Chronic lymphocytic leukemia Disease Ontology: DOID:1040
OMIM: 151400
Orphanet: ORPHA67038
 Approved for use in combination with chemotherapy in patients who have received no prior therapy.
Follicular lymphoma Disease Ontology: DOID:0050873
 Approval is for a combination therapy of obinutuzumab with bendamustine, followed by obinutuzumab monotherapy.